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Multiple myeloma is a malignant plasma cell disorder that accounts for approximately 10% of all hematologic cancers. It is
characterized by accumulation of clonal plasma cells, predominantly in the bone marrow. The prevalence of type 2 diabetes is
increasing; therefore, it is expected that there will be an increase in the diagnosis of multiple myeloma with concomitant diabetes
mellitus. The treatment of multiple myeloma and diabetes mellitus is multifaceted. The coexistence of the two conditions in a
patient forms a major challenge for physicians.
1.Introduction
It is estimated that around 8–18% of cancer patients
have diabetes. Diabetes and cancer are two overwhelming
conditions for both patients and clinicians. The treatment of
diabetes in the presence of cancer is a major challenge for
physicians. Maintaining adequate glucose control is a crucial
factor in preventing infections in at-risk cancer patients
[1]. Multiple myeloma is a fatal neoplasm of the B cell
characterizedby expansion of malignant plasma cells, mostly
in the bone marrow which in return leads to one or more
clinical manifestation of bone destruction, hypercalcemia,
anemia, and renal insuﬃciency. The disease accounts for
approximately 10% of all hematologic cancers [2].
Since the prevalence of type 2 diabetes is increasing
worldwide, an increase in the diagnosis of MM with
concomitant DM is expected. Therefore, physicians treating
such patients should be fully aware of the potential eﬀect of
MMtreatmentonglucosemetabolisminthispopulation[3].
Multiple reports have linked diabetes to increased
risk of cancer mainly pancreatic, liver, colon, breast, and
endometrial cancer [4]. In a phase 3 Apex trial in patients
with relapsed multiple myeloma by Richardson et al., 18%
patientshadeitherabaselineglycosylatedhemoglobinhigher
than normal upper level or a history of diabetes [5]. In other
reports, the prevalence was between 11% and 22% [6, 7].
Is there evidence about a causal relationship? Although
results in the literature are contradictory, in a recent study
conducted by Khan et al. there was no association between
selfreporteddiabetesandmultiplemyeloma[8],whereasthe
highest level of postload glucose was associated with risk of
mortality from multiple myeloma (HR, 3.06; 95% CI, 1.05–
8.93) in another study by Chiu et al. [9].
Therehavebeenoutstandingimprovementsoverthepast
decade in the area of initial therapy of newly diagnosed
multiple myeloma. Several large trials investigated the role
of treatment regimens involving one or more of the most
recent medications. [10–18]. Many factors govern the choice
of initial therapy for MM. The patient’s age, performance
status, eligibility for stem cell therapy, and most importantly
the presence of disease-related complications as well as other
comorbid conditions such as diabetes and obesity are factors
to consider before the choice of initial therapy. Introduction
of new more eﬃcient treatments, in addition to expansion
in the use of high-dose therapy, is a factor that contributed
to better prognosis with an eﬀect on diabetes control.
Novel agents have been introduced, namely, bortezomib,
thalidomide, and lenalidomide. In addition to these three
novel agents, other targeted therapies are being investigated
in preclinical and clinical studies as well as treatments
combiningtheseagentswithothernovelagentstogetherwith
traditional drugs that are used commonly. These trials are2 ISRN Endocrinology
exhibiting a promising future in the treatment of myeloma.
However, the safety and eﬃcacy of combinations integrating
these novel agents on diabetes control and complications is
not well understood [19].
2. Glucose Control inMultiple Myeloma
Dexamethasone- and prednisone-based regimens are part of
the conventional and new methods to treat newly diagnosed
or recurrent/multiple myeloma, These medications raise
blood glucose through increased insulin resistance, gluco-
neogenesis,glycogenolysis,anddecreasedinsulinproduction
and secretion [20]. Glucocorticoids are frequently used in
high doses for a short term during chemotherapy protocol
whereas lower doses are also used to prevent chemotherapy-
induced nausea and vomiting.
Dexamethasone was shown to be more harmful to the
diabetes proﬁle in a study by Facon et al. where the inves-
tigators compared dexamethasone and Prednisone-based
regimens with standard melphalan prednisone in newly
diagnosed MM patients ineligible for high-dose therapy. The
morbidity associated with dexamethasone-based regimens
was signiﬁcantly higher than with melphalan prednisone
including severe diabetes [21]. We suggest that patients
should be screened for diabetes before starting glucocorti-
coid treatment and monitored closely. Glucocorticoid-free
regimens can be used in patients with diabetes mellitus [22].
Risk factors for glucocorticoid-induced diabetes including
obesity, age, family history of diabetes, personal history of
gestational diabetes, and high-dose steroids are all prompts
for a more stringent screening [23]. Oral hypoglycemic
agents can be continued if they seem to be enough for
adequate glycemic control; however, patients will frequently
need insulin as a an add on therapy. Patients already on
insulin will most likely require basal and preprandial doses,
up to two to three times their usual dose to adequately
control their blood sugar levels [20, 23, 24].
Patients with multiple myeloma may experience nausea
and vomiting in addition to poor appetite and thus missed
meals which put patients at risk of hypoglycemia. Treating
the nausea and vomiting by antiemetics; advising patients
to eat small frequent meals and to avoid sweet, salty, or
spicy foods since they may aggravate nausea and vomiting
will minimize the risk of hypoglycemia in such patients.
Additionally, using a short acting secretagogue (nateglinide
or repaglinide) instead of a usual sulfonylurea (glimepiride,
glipizide, or glyburide) may be a better option for postpran-
dial hyperglycemia to avoid hypoglycemia; moreover, rapid
actinginsulinsuchaslispro,aspart,orglulisinegivendirectly
after meals can be equally eﬃcacious.
2.1. Does Glycemic Control Aﬀect Outcome in Multiple
Myeloma? In a retrospective study done by Brunello et
al. hyperglycemia correlated with nonhematological toxicity
(neuropathy, fever, fatigue) in NHL patients [25]. Further
studies are needed to assess the impact of hyperglycemia
on hematological and nonhematological toxicity in patients
with multiple myeloma.
Novel treatments in diabetes mellitus such as dipeptidyl
peptidase IV (DPP4) inhibitors and Glucagon like peptide
1(GlP1) agonists can be theoretically used to control steroid-
induced hyperglycemia or diabetes in MM; nevertheless,
there are no studies till the present time that have looked
into the eﬀect of these new agents on cancer in general
and multiple myeloma speciﬁcally. Some reports in the
literature mentioned the possible adverse eﬀects of DPP4
on parameters of immunity. Cells of the immune system
such as thymocytes, T and B lymphocytes, and NK cells
contain a cell surface protein called CD26; this latter has a
DDP4 enzymatic activity and its activation was shown to
increase the proliferation and/or activation of T cells and
IL2 production. In addition, in vitro studies showed that
DPP4 inhibitors modify T cell function by decreasing IL2,
IL10, and interferon γ and increasing transforming growth
factor β1[ 26]. CD26 was also suggested to be implicated in
autoimmunity and T cell response to external stimuli [26].
Likewise GLP1 receptor signaling was also found to regulate
lymphocyte proliferation and maintenance of regulatory
peripheral regulatory T cells in mice [27]. The eﬀect of
these novel antidiabetics on the immune system is still not
apparent, and thus more research is needed on the use of
such agents in patients with multiple myeloma and other
lymphoproliferative disorders.
3. Thalidomide-Induced Hyperglycemia
In a study by Iqbal et al., thalidomide 150mg or placebo was
administered for 3 weeks in a crossover design to 6 patients
with diabetes [28]. Insulin resistance was increased by 31%
decreased insulin-stimulated peripheral glucose uptake, and
glycogen synthesis was decreased by 48%; this was assessed
by performing isoglycemic-hyperinsulinemic clamps before
and after therapy. In another study by Wilson and Vallance-
Owen [29], mothers giving birth to children with congenital
malformations in 1966 were studied for insulin antagonism
using a bioassay (rat diaphragm assay). 5 Out of 6 mothers
(83%) exposed to thalidomide in their ﬁrst trimester had
antagonism to insulin whereas 14 out of 50 (28%) mothers
in the control group had insulin antagonism. In 2001, Figg et
al. showed that decreasing the dose of thalidomide improved
hyperglycemia [30]. In 2003, a case report on thalidomide-
induced severe hyperglycemia was published by Pathak et al.
[31]. Overall, larger studies are needed to assess this risk and
its implications on diabetes and multiple myeloma outcome.
4.Multiple Myeloma andDiabeticNeuropathy
Peripheralneuropathyisacommonprobleminpatientswith
multiple myeloma and is also a common complication of
type 2 diabetes. The condition may occur before initiating
treatment [32]. In a recent study by Borrello et al., the
incidence of peripheral neuropathy in patients with newly
diagnosed multiple myeloma prior to the administration
of any therapy was 15% which suggests that peripheral
neuropathy is a symptom of the disease itself [33]. Fur-
thermore treating multiple myeloma might complicate theISRN Endocrinology 3
neuropathy; the latter is associated with agents used to
treat the disease, such as bortezomib [7], thalidomide
[34], and vincristine [35]. Recently Wilson and Vallance-
Owen have suggested an interaction between myeloma-
related factors and the patient’s genetic background in
the development of treatment-induced peripheral neuropa-
thy, with diﬀerent molecular pathways being implicated
in bortezomib-induced and vincristine-induced peripheral
neuropathy [29]. Patients frequently complain of sensory
symptoms, pain in a stocking-and-glove distribution, and
proprioception changes that may aﬀect normal daily living
activities [36]. Studies looking into the association between
bortezomib-induced neuropathy and diabetic neuropathy
have yielded contradictory results. Badros et al. showed that
the highest risk and grade of bortezomib neurotoxicity was
observedinpatientswhohadbaselineperipheralneuropathy
and diabetes mellitus [7]. In the APEX trial, more than
300 patients with refractory or relapsed multiple myeloma
were randomized to bortezomib or dexamethasone. The
investigators evaluated peripheral neuropathy. In this trial,
the incidence and severity were not aﬀected by age, number
or type of prior therapies, baseline glycosylated hemoglobin
level, or diabetes history [37]. Moreover the incidence
of grade 3 peripheral neuropathy was actually lower in
patients with a history of diabetes. The authors hypothesized
that bortezomib-associated neuropathy is mechanistically
distinct and that prior exposure to other neurotoxic agents
or history of diabetes should not exclude patients from
bortezomibtherapy[37].Finallyinamorerecentsubanalysis
of the phase 3, Vista trial that assed the frequency, charac-
teristics, reversibility and prognostic factors for bortezomib
associated peripheral neuropathy in newly diagnosed multi-
ple myeloma patients ineligible for high-dose therapy who
received bortezomib plus melphalan prednisone. Preexisting
diabetes did not aﬀect the overall rate of peripheral neu-
ropathy whereas baseline neuropathy was the only consistent
risk factor for any peripheral neuropathy (HR 1.785, P =
0.0065), grade ≥2 peripheral neuropathy (HR 2.205, P =
0.0032), and grade ≥3 peripheral neuropathy (HR 2.438,
P = 0.023); moreover, bortezomib-associated peripheral
neuropathy was reversible [31]. Vincristine, the oldest and
most neurotoxic of the class, is still widely used in leukemias,
lymphomas, myeloma, and various sarcomas. Peripheral
neuropathy is the most common dose-limiting toxicity of
vincristine. Symptoms range from peripheral sensorimotor
loss to autonomic dysfunction related to paralytic ileus,
orthostasis, and sphincter problems [28]. Thalidomide is
an oral immunomodulatory and antiangiogenic agent. In
the 1990s, it showed good results in multiple myeloma
patients, and it received US Food and Drug Administration
(FDA) approval in 1998. Thalidomide-induced peripheral
neuropathy is characterized by being mainly distal sensory
and less commonly motor. Its incidence varies from 25%
to 75% [32]. The major predictors to thalidomide-induced
peripheral neuropathy seem duration of treatment and
possibly baseline neuropathy [38]. Peripheral neuropathy is
a common complication of diabetes mellitus and multiple
myeloma. Therefore, patients receiving a chemotherapeutic
agentthatmightexacerbateperipheralneuropathyshouldbe
closelymonitored.Asforbortezomib-associatedneuropathy,
it was shown to be reversible in the majority of patients
after dose reduction or discontinuation [6]. We suggest
that newly diagnosed patients with multiple myeloma be
clinically assessed for peripheral neuropathy prior to start-
ing treatment and regularly assessed thereafter. The exact
duration of posttreatment monitoring remains controversial
and is dependent on diabetic history, baseline neuropathic
symptoms, and the type and dose of chemotherapy received.
Patients should also be educated about the symptoms
to ensure early detection of neuropathy [38]. Stringent
glycemic control may reduce the risk of developing diabetic
neuropathy by 60% [23]. There are no consensus guidelines
about diabetes management in multiple myeloma, but
we can extrapolate from previous reports about diabetes
management in cancer patients that ﬁrst the progressive loss
of nerve function associated with diabetic neuropathy can
be slowed down by adequate glycemic control [25], and
the latter is designated as the only modiﬁable risk factor
for diabetic neuropathy [39]. The household environment
should be adjusted to prevent falls, and water temperature
should be decreased to prevent burns and use night lights.
Proper foot and nail care should be emphasized to prevent
ulcers and infection [40].
5. Multiple Myeloma andNephropathy
Renal insuﬃciency is a common complication in patients
with diabetes. It is also a common accompaniment of
multiple myeloma. The presence of such complication in
multiple myeloma patients along with diabetes creates an
extra burden to the patient as well as the physician. It was
reported that nephropathy is a poor prognostic indicator for
survival in these two comorbid conditions [41].
Approximately, 20% of patients with newly diagnosed
multiple myeloma can present with renal insuﬃciency, and
up to 40% of patients with type 2 diabetes mellitus can
be aﬀected with diabetic nephropathy [42]. Nephropa-
thy associated with multiple myeloma is usually due to
abnormal light chains deposition. When this deposition
is tubulopathic, it can lead to cast nephropathy in the
distal tubules or more rarely Fanconi syndrome or type 2
renal tubular acidosis in the proximal tubules. Alternatively,
when the deposition is glomerulopathic, it can lead to
monoclonal immunoglobulin deposition disease or light
chainamyloidosis [43,44].During thecourseof themultiple
myeloma, approximately half of the patients will experience
renal insuﬃciency either from the disease itself or as a
complication of treatment [45]. The combination of new
therapies for multiple myeloma causes rapid reductions
of the monoclonal protein especially the free light chain
which is the culprit for the cast nephropathy that is consid-
ered the most common renal lesion in multiple myeloma.
Bortezomib and thalidomide are not cleared by the kidneys
so they can be administered without dose adjustments in
patients with renal failure. On the other hand, treatment
with Lenalomide which is cleared renally requires careful
creatinine monitoring and dose adjustments. Lenalomide4 ISRN Endocrinology
has been shown to be eﬃcacious and improved the kidney
function in patients [46]. Dehydration, use of nonsteroidal
anti-inﬂammatory drugs, hypercalcemia, and use of contrast
agents are considered precipitating factors for renal failure in
patients with concomitant diabetes and multiple myeloma.
Special considerations should be taken in such patients.
Since there are no reports that looked into this issue, it’s of
great importance to keep in mind that avoiding and treating
the risks may ameliorate the severity of nephropathy, and
adequate glycemic control may slow down the progression
of diabetic nephropathy in these patients [47].
6. MultipleMyeloma and Retinopathy
The ocular manifestations can be the ﬁrst presentation of
the disease, and the mechanism includes direct inﬁltration
or extramedullary plasmacytomas displacing surrounding
tissues or by deposition of light chain in ocular tissues or
by hyperviscosity state. The ophthalmic ﬁndings include
proptosis, diplopia, lid ecchymosis, xanthomatosis, conjunc-
tival and corneal crystalline and noncrystalline deposits,
scleritis, episcleritis, secondary glaucoma, ciliary body cysts,
ciliochoroidal eﬀusion, uveal plasmacytoma, hyperviscosity
retinopathy, retinal vasculitis, detachment of sensory retina
and retinal pigment epithelium, and neuroophtalmic man-
ifestations [48]. All These ﬁndings might complicate the
diabetic retinopathy in patients with coexistent multiple
myeloma and diabetes.
We suggest the all patients with multiple myeloma
undergo ophthalmic evaluation at the time of diagnosis and
be followed up closely by an ophthalmologist if baseline
diabetic retinopathy was found. Additionally, strict glucose
control is imperative in these patients.
7. MuliplteMyeloma and
CardiovascularDiseases
Diabetes is well known to be associated with increased risk
of coronary heart disease and stroke [49]. Multiple myeloma
can also possibly predispose to these 2 macrovascular com-
plications. The presence of these conditions simultaneously
worsens the prognosis and creates a bigger challenge to the
treating physician.
Recently a case report about ischemic heart disease in
a patient with multiple myeloma receiving bortezomib and
dexamethasone has been published. The authors suggested
that the mechanism could be explained by the inhibition
of proteasome activity. This inhibition increases endothelial
progenitor cell apoptosis [50] and decreases its proliferation
which aﬀects endothelial nitric oxide synthase/nitric oxide
leading to coronary spam [51–53]. Moreover, an age-
dependent decrease in ubiquitin-proteasome activity has
been associated with injury of heart muscles and morbidity
ofcardiovasculardiseases.Thebortezomib-induceddecrease
in proteasome activity has been linked to increased rate
of apoptosis in smooth muscle cells [54], thus, causing
a weakening of the ﬁbrous cap and eventually leading to
atheroscleroticplaqueinstabilityandrupture[55–57].More-
over, multiple myeloma has been associated with cardiac
amyloidosiswhichcanexacerbatetheheartfailurethatmight
already be present in patients with diabetes mellitus [58].
Strokecanbeacomplicationofmultiplemyelomaaspart
of the hyperviscosity syndrome associated with the disease
due to the paraproteinemia [59]. This might be an added
risk to patients with diabetes mellitus who already have an
increased risk.
8. Conclusion
Diabetics with multiple myeloma constitute a challenging
speciﬁc population to physicians. Multiple myeloma by itself
and its related treatments can complicate the microvas-
cular and macrovascular complications of diabetes. The
treating physician has to recognize the treatment-related
complications and closely follow up diabetic patients for the
emergence or the worsening of hyperglycemia, neuropathy,
nephropathy, or retinopathy in addition to cardiovascular
diseases. In addition, maintaining adequate blood glucose
levels reduces the risk of infection in patients with multiple
myeloma and decreases the risk and severity of diabetic
microvascularcomplications,thus,minimizingtheincreased
morbidity of multiple myeloma [60].
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